Literature DB >> 15551326

Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study.

Stuart I Collins1, Saeideh Mazloomzadeh, Heather Winter, Terry P Rollason, Penny Blomfield, Lawrence S Young, Ciaran B J Woodman.   

Abstract

Cross-sectional studies have suggested that compared with women who delay the start of their sexual career, those who first have intercourse soon after menarche are more susceptible to cervical human papillomavirus (HPV) infection and thus have a greater risk of cervical neoplasia. We describe, using longitudinal observations, how the risk of infection with HPV varies with the interval between menarche and first intercourse in 474 women aged 15-19 recruited within 12 months of first intercourse and before the acquisition of a second sexual partner. One hundred forty-five women became HPV-positive; the cumulative risk of HPV infection 3 years after first intercourse was 45.0% (95% CI = 37.9-51.2). In univariate analyses, the hazards ratio (HR) of HPV infection increased significantly with age at first intercourse (HR = 1.212 per year; 95% CI = 1.050-1.398), partner age (HR = 1.084 per year; 95% CI = 1.045-1.125) and when women reported a sexually experienced partner (HR = 2.794; 95% CI = 1.804-4.326); the interval between menarche and first intercourse was a significant predictor of infection, with an increase in the HR of 12.9% for every year of increase in this interval (95% CI = 2.1%-24.9%). In a multivariate analysis, compared with women who first had intercourse within 3 years of menarche, those who postponed first intercourse beyond this time had a greater risk of infection (HR = 1.581; 95% CI = 1.113-2.245) after controlling for age and sexual experience of partner. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15551326     DOI: 10.1002/ijc.20732

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis.

Authors:  Ann N Burchell; Allita Rodrigues; Veronika Moravan; Pierre-Paul Tellier; James Hanley; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

2.  Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion.

Authors:  Alex Chen; Scott A McKinley; Simi Wang; Feng Shi; Peter J Mucha; M Gregory Forest; Samuel K Lai
Journal:  Biophys J       Date:  2014-05-06       Impact factor: 4.033

3.  Time since first sexual intercourse and the risk of cervical cancer.

Authors:  Martyn Plummer; Julian Peto; Silvia Franceschi
Journal:  Int J Cancer       Date:  2011-08-12       Impact factor: 7.396

4.  Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection.

Authors:  Ali Rowhani-Rahbar; James P Hughes; Laura A Koutsky
Journal:  Sex Transm Dis       Date:  2009-04       Impact factor: 2.830

5.  Prevalence and Risk Factors for Genital Human Papillomavirus Infections Among Women in Southwest Nigeria.

Authors:  Y T Nejo; D O Olaleye; G N Odaibo
Journal:  Arch Basic Appl Med       Date:  2018-05-04

6.  Oral and genital HPV genotypic concordance between sexual partners.

Authors:  Camila Maria Beder Ribeiro; Iracema Ferrer; Andreza Barkokebas Santos de Farias; Débora Diniz Fonseca; Igor Henrique Morais Silva; Luiz Alcino Monteiro Gueiros; Alessandra Tavares Carvalho; Stephen Ross Porter; Jair Carneiro Leao
Journal:  Clin Oral Investig       Date:  2013-03-14       Impact factor: 3.573

7.  Risk of female human papillomavirus acquisition associated with first male sex partner.

Authors:  Rachel L Winer; Qinghua Feng; James P Hughes; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

Review 8.  Clinical trials of human papillomavirus vaccines and beyond.

Authors:  Matti Lehtinen; Joakim Dillner
Journal:  Nat Rev Clin Oncol       Date:  2013-06-04       Impact factor: 66.675

9.  Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Authors:  Lucia Six; Sepp Leodolter; Heather L Sings; Eliav Barr; Richard Haupt; Elmar A Joura
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Past and future of prophylactic ablation of the cervical squamocolumnar junction.

Authors:  Silvia Franceschi
Journal:  Ecancermedicalscience       Date:  2015-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.